- Home
- MUJ vs TRVI Comparison
MUJ vs TRVI Comparison
Compare MUJ & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- TRVI
- Stock Information
- Founded
- MUJ 1998
- TRVI 2011
- Country
- MUJ United States
- TRVI United States
- Employees
- MUJ N/A
- TRVI N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- TRVI Health Care
- Exchange
- MUJ Nasdaq
- TRVI Nasdaq
- Market Cap
- MUJ 606.3M
- TRVI 725.7M
- IPO Year
- MUJ N/A
- TRVI 2019
- Fundamental
- Price
- MUJ $11.39
- TRVI $7.96
- Analyst Decision
- MUJ
- TRVI Strong Buy
- Analyst Count
- MUJ 0
- TRVI 9
- Target Price
- MUJ N/A
- TRVI $20.72
- AVG Volume (30 Days)
- MUJ 108.0K
- TRVI 3.1M
- Earning Date
- MUJ 01-01-0001
- TRVI 11-05-2025
- Dividend Yield
- MUJ 4.36%
- TRVI N/A
- EPS Growth
- MUJ N/A
- TRVI N/A
- EPS
- MUJ N/A
- TRVI N/A
- Revenue
- MUJ N/A
- TRVI N/A
- Revenue This Year
- MUJ N/A
- TRVI N/A
- Revenue Next Year
- MUJ N/A
- TRVI N/A
- P/E Ratio
- MUJ N/A
- TRVI N/A
- Revenue Growth
- MUJ N/A
- TRVI N/A
- 52 Week Low
- MUJ $9.74
- TRVI $2.36
- 52 Week High
- MUJ $11.70
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- MUJ 68.02
- TRVI 51.91
- Support Level
- MUJ $10.88
- TRVI N/A
- Resistance Level
- MUJ $11.49
- TRVI $9.92
- Average True Range (ATR)
- MUJ 0.09
- TRVI 0.73
- MACD
- MUJ 0.03
- TRVI -0.24
- Stochastic Oscillator
- MUJ 83.61
- TRVI 80.24
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.